10x Genomics (TXG) is in focus after unveiling its Atera spatial biology platform at the AACR Annual Meeting, pairing whole transcriptome and single cell tissue analysis with new cloud and sample submission services.

The Atera launch comes after a strong run, with a 28.58% year to date share price return and a very large 1 year total shareholder return, although the 3 and 5 year total shareholder returns remain sharply negative, which can temper enthusiasm.

If spatial biology is on your radar and you want to see what else is out there, this is a good moment to scan 32 healthcare AI stocks

With the stock up 28.58% year to date and trading below both its analyst price target and intrinsic value estimate, is this an underappreciated spatial biology leader, or has the market already priced in Atera driven growth?

Most Popular Narrative: 6.1% Overvalued

The most followed valuation narrative puts 10x Genomics’ fair value at $20.14, slightly below the last close at $21.37, and ties that gap directly to how quickly earnings might scale from current loss levels.

If 10x Genomics''s profit margin were to converge on the industry average, you could expect earnings to reach $110.2 million (and earnings per share of $0.77) by about March 2029, up from -$43.5 million today.

In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 32.7x on those 2029 earnings, up from -54.0x today.

Want to understand what has to go right for margins, revenue and future multiples to line up with that fair value? The narrative leans on a carefully staged earnings ramp, a specific revenue run rate, and a premium but not extreme earnings multiple. Curious which assumptions do the heavy lifting in that model.

Result: Fair Value of $20.14 (OVERVALUED)

However, that story can quickly change if academic and government funding stays soft, or if instrument discounting and lower priced consumables keep squeezing margins.

Another Way To Look At Value

The fair value narrative points to 10x Genomics as 6.1% overvalued at $21.37 versus a $20.14 estimate, yet our DCF model paints a different picture, with shares trading at a 34.8% discount to an implied future cash flow value of $32.80. Which story do you think fits the risk and funding backdrop better?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out 10x Genomics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 53 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals on value and sentiment, do these risks and rewards balance out enough for you? Take a closer look at the details and weigh the 2 key rewards and 2 important warning signs.

Ready To Find More Investment Ideas?

If 10x Genomics has you thinking about what else might fit your portfolio, use this moment to hunt for fresh ideas before the next wave of results hits.

• Spot potential value standouts by scanning 53 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect their strengths.
• Prioritise resilience first and check out 72 resilient stocks with low risk scores if you want companies that score well on financial strength and risk metrics.
• Get ahead of the crowd by reviewing screener containing 25 high quality undiscovered gems that combine solid financials with limited current attention from the wider market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.